E2F1 and breast carcinoma: In addition to the promising therapeutic properties of the TMCG/DIPY combination, we described in this study a coordinate mechanism by which simultaneous demethylation of DNA and E2F1 contributes to the reactivation of the tumour suppressor RASSF1A in breast cancer cells.